United States: CMS Finalizes Changes To Medicare Clinical Lab Test Payment Policy, Pushes Back Effective Date To 2018

On June 23, 2016, the Centers for Medicare & Medicaid Services (CMS) is publishing a major final rule to base Medicare clinical laboratory fee schedule (CLFS) reimbursement on private insurance payment amounts, as required by the Protecting Access to Medicare Act of 2014 (PAMA). In an important change from the proposed rule, CMS will implement the new payment policy beginning January 1, 2018, rather than in 2017. Once in effect, the impact will be significant; CMS estimates that the final rule will reduce Medicare payments by $390 billion in FY 2018 and by $3.93 billion through FY 2025. The following is an overview of the complex new payment methodology.

The final rule establishes both reporting and payment provisions for clinical diagnostic laboratory tests (CDLTs), with different requirements for a subset of CDLTs determined to be "advanced diagnostic laboratory tests" (ADLTs). As defined by PAMA, an ADLT is a CDLT that is offered and furnished only by a single laboratory and not sold for use by a laboratory other than the original developing laboratory (or a successor owner) and that meets one of the following criteria:

  1. the test is an analysis of multiple biomarkers of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or proteins combined with a unique algorithm to yield a single patient-specific result (CMS did not adopt a proposal to exclude protein-only tests from the definition of ADLTs);
  2. the test is cleared or approved by the Food and Drug Administration; or
  3. the test meets other similar criteria established by the Secretary (CMS is not establishing additional criteria at this time).

The final rule requires laboratories to submit evidence to support their application for ADLT status.

Reporting Requirements.

With regard to reporting, the rule requires "applicable laboratories" to report to CMS specified "applicable information" about payment rates paid by private payors for each CDLT and the volumes of tests furnished during a specified period. Under the final rule, CMS defines an ''applicable laboratory'' as a laboratory that receives more than 50% of its Medicare revenues from services paid by under the CLFS and the Medicare physician fee schedule (PFS). In a change from the proposed rule, CMS defines a laboratory at the National Provider Identifier (NPI) level, rather than the Taxpayer Identification Number (TIN) level (although reporting will be at the TIN level). In addition, CMS will exempt from the definition of applicable laboratory those low-expenditure facilities that receive less than $12,500 in Medicare revenues from the CLFS during the data collection period (compared to the proposed threshold of $50,000); note that the $12,500 threshold does not apply with respect to a single laboratory that furnishes an ADLT. CMS estimates that the low expenditure criterion will exclude about 55% of independent laboratories and about 95% of physician office laboratories from the private payor data reporting obligation.

The final rule specifies that applicable information to be reported includes: (1) each private payor rate for which final payment has been made during the data collection period; and (2) the associated volume of tests performed corresponding to each private payor rate. Data will be reported by Healthcare Common Procedure Coding System (HCPCS) code. As mandated by the statute, CMS defines "private payor'' as a health insurance issuer or a group health plan, a Medicare Advantage plan, or a Medicaid managed care organization. CMS defines the private payor rate as the final amount that was paid by a private payor for a CDLT after all private payor price concessions are applied, and does not include price concessions applied by a laboratory. CMS excludes data from tests for which payment is made on a capitated basis. Furthermore, only private payor payment rates for CDLTs paid under the CLFS are considered for private payor rates; payment rates for laboratory tests paid only under the PFS are not considered be private payor rates and should not be reported as applicable information. CMS intends to publish a list of HCPCS codes subject to reporting on its website.

Payment Provisions

With regard to payment, subject to certain exceptions, the payment amount for a CDLT furnished on or after January 1, 2018 (other than new tests and ADLTs) will equal the weighted median of private payor rates determined for the test, based on the data reported by laboratories during the applicable data collection period. The final rule also reflects a PAMA provision preventing test payment amounts from being reduced by more than 10% compared to the previous year's payment for the first three years of the policy (2018-2020 under the revised implementation schedule) and by more than 15% for the subsequent three years (2021-2023). For new and existing tests (other than new ADLTs) for which CMS receives no applicable information to calculate a weighted median, CMS will determine payment rates by using crosswalking or gapfilling.

New ADLTs will be paid at actual list charge for three quarters, beginning on the first day of the first full calendar quarter following the later of (1) the date a Medicare Part B coverage decision for the test is made or (2) the date ADLT status is granted by CMS. CMS defines actual list charge as "the publicly available rate on the first day the new ADLT is obtainable by a patient who is covered by private insurance, or marketed to the public as a test a patient can receive, even if the test has not yet been performed on that date." As authorized by PAMA, if the actual list charge during the new ADLT initial period is subsequently determined to be greater than 130% of the Medicare payment amount based on the weighted median of private payor rates that applies after the new ADLT initial period, CMS will recoup the difference between the actual list charge and 130% of the weighted median private payer rate. Once the new ADLT initial period is over, payment will be based on the weighted median private payer rate.

Implementation Schedule

The final rule establishes the following schedule for implementation of the new reporting and payment methodology for purposes of setting CY 2018 rates:

  • First data collection period for determining CY 2018 CLFS payment rates: January 1, 2016 — June 30, 2016.
  • First data reporting period for reporting entities to report private payor rate data to CMS for determining CY 2018 CLFS payment rates: January 1, 2017 — March 31, 2017.
  • Annual laboratory public meeting for new tests (that are not new ADLTs): mid-July 2017. CMS will use crosswalking or gapfilling to set rates for such tests for which there is no private payor data collected for CY 2018.
  • Publication of preliminary CLFS rates for CY 2018: early September 2017 (with a public comment period of approximately 30 days).
  • CMS posts final CY 2018 CLFS rates on the CMS website: early November 2017.
  • Implementation date of new CLFS: January 1, 2018.

Subsequent data collection and reporting periods for CDLTs (except for ADLTs) will follow this data collection and reporting schedule every three years, while reporting of private payor rates for ADLTs will follow this schedule on an annual basis.

The final rule also addresses a variety of other definitions, implementation details, and policy issues, including: certification of submitted information; civil monetary penalties for applicable laboratories that fail to report or that make a misrepresentation or omission in reporting applicable information; confidentiality and public release of limited data; temporary coding for new tests; and the potential designation of Medicare Administrative Contractors (MACs) to establish coverage policies and potentially process claims for laboratory tests (CMS is not adopting changes in lab contracting functions in this rule).

CMS has scheduled a July 6, 2016 educational call to discuss the rule.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions